In this issue:
KTE-X19 CAR T-cells in relapsed/ refractory mantle-cell lymphoma
CAR T-cell therapy during the COVID-19 pandemic
COVID-19 and immunotherapy in metastatic lung cancer
Access to IL-6-targeting therapies in COVID-19
Incidence and risk factors associated with a PCTT syndrome
Blinatumomab consolidation and maintenance in relapsed/ refractory B-ALL
Anti-BCMA BITE (AMG 420) induces responses in multiple myeloma
Immune-related adverse events: indicators of pembrolizumab activity in stage 3 melanoma
Are immune-related adverse events associated with the ICI efficacy in cancer?
Value and affordability of CAR T-cell therapies in the US
Download PDF